top of page
Science Woman_Dark Red-01.png

PIPELINE

Diversified pipeline with large potential

Mission Vision

Rethinking drug delivery

Rebel Medicine’s R&D pipeline is designed to address important unmet medical needs, with the potential to make a significant difference for patients. New product candidates are based on our proprietary drug delivery technologies.

Small icon.png

R&D PIPELINE

Products in development

Discovery

Preclinical

IND/IDE-enabling

Clinical

Registration

Alevatrix

Postoperative pain

ALX-UL

Postoperative pain

RBL-DEX

Osteoarthritis

RBL-DEX

Low back pain

RBL-OI

Diabetes

Alevaderm

Painful dermal injury

Alevatrix

Extended-release bupivacaine gel

Alevatrix is an injectable long-acting formulation of the local anesthetic, bupivacaine, under development to enable opioid-free management of postoperative pain. The product is based on Rebel Medicine’s proprietary Lipitrix injectable gel technology and will be packaged in a ready-to-use, prefilled syringe that can be used in both regional anesthesia via nerve blocks and local anesthesia via instillation. 

Opioid-based medications are a mainstay of postoperative pain management today with approximately 80% of surgical patients receiving opioid prescriptions after surgery. However, their use is associated with a variety of adverse events, prolonged hospital length of stay and increased costs of care. The pain after surgery is most intense in the first 72 hours, after which non-opioid systemic medications such as acetaminophen and NSAIDs are sufficient for most patients. Alevatrix has demonstrated in large animal models that it can control pain locally through the first 72-96 hours. By minimizing or eliminating the need for opioids after surgery, Alevatrix has the potential to reduce the cost and improve outcomes for patients undergoing surgery.

Rebel Medicine has performed extensive preclinical evaluations of Alevatrix in validated and translatable large animal models and is targeting 72-96 hours of pain relief after a single administration. IND-enabling studies were initiated in Q1 2023 and Rebel Medicine expects to submit for IND opening by EOY 2023. 

bottom of page